Accordingly, current preclinical efforts are focused on optimizing the PSMA-targeting moiety [20,25], linker composition [12,26], and albumin-binding motif [20,26] to maximize the tumor-to-kidney radiation dose ratios. This evidence concerns the gene FOLH1 and neoplasm.